Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HyperCard2 study of empagliflozin and insulin isophane effects on cardiac function in men with type 2 diabetes
2017-002101-35Phase 4Completed
- Sponsor
- Sten Madsbad
- Start
- Jun 2017
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4 trial of empagliflozin and insulin isophane in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Sten Madsbad. Started Jun 2017; status: completed.
02
Drugs
empagliflozininsulin isophane
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2017-002101-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002101-35.